Impact Therapeutics Announces Completion Of Series D1 Financing
PRIVATEMar 14, 2022
Round Type
Series D
ShanghaiBiotechnologyHealth CareScience And Engineering
Description
IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that participated in this round include new investors Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management led by Sam Isaly, along with existing shareholders LAV (Lilly Asia Ventures), China Summit, and Yuexiu. Proceeds will be used to accelerate the development of its synthetic lethality programs, many of which are showing best-in-class potential.
Who to call at IMPACT Therapeutics, and when
A new round usually means IMPACT Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day IMPACT Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at IMPACT Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at IMPACT Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
IMPACT Therapeutics
Location
Shanghai, Shanghai, China
About
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipelines of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib's preliminary clinical data demonstrated superior tolerability and wider therapeutic windows compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received IND Clearance by the FDA to start clinical studies in the U.S. and submitted clinical application in China. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China. For more information, please visit www.impacttherapeutics.com/en/.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment IMPACT Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ShanghaiBiotechnologyHealth CareScience And Engineering